explore -WSS

explore

author：explore 2025-10-02 22:41:40 - browse：52221

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Exact Sciences stock tumbles despite strong cancer detection sales

leisure time

WSS

Cholera vaccine supply gets boost as demand surges globally

CMS should re

Close Medicare's dangerous gaps in addiction treatment coverage

Medical bills so high, Medicare adding extra digits to claim forms

Americans' trust in science, scientist continues decline: Report

Getting Alzheimer's drug Leqembi to patients can be a challenge

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Duchenne breakthrough therapy leaves behind pioneering families

FDA needs staff influx to meet gene therapy needs, Marks says

Apple is now the first public company to be valued at $3 trillion

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Activists slam private health insurers over coverage restrictions

Pregnancy discrimination could be enabled by AI

Cancer drug shortages should be causing more outrage

Congenital heart disease patients face new threat of heart failure

Jerome Adams on the need for new antivirals for Covid

SCOTUS to consider access to abortion pill mifepristone

entertainment

Bird flu in milk supply is likely coming from asymptomatic cows

Patients' immediate access to test results puts radiologists in a bind

Cholera vaccine supply gets boost as demand surges globally

Element Biosciences CEO lays out genome sequencing strategy

Pfizer plans to depart BIO

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Wikipedia

leisure time

focus

Wikipedia